© Copyright Our Wall
Market Overview: The global
market for Hepatitis A vaccines displayed significant strength in 2020 and
is poised for steady revenue growth throughout the forecast period. Key drivers
of this growth include the increasing prevalence of chronic diseases,
government initiatives aimed at promoting health awareness, and the vaccine's
high effectiveness in disease treatment.
Hepatitis is a liver inflammation caused by either infectious
or non-infectious factors. The Hepatitis A vaccine is a preventive measure with
an efficacy rate of around 95% and a protection duration of at least twenty
years. It is administered through injection and was first approved in Europe in
1991 and in the United States in 1995. The World Health Organization recognizes
it as an essential medicine and recommends universal vaccination, as natural
immunity typically develops during childhood.
Get a sample copy of theHepatitis A Vaccine Market report: https://www.reportsanddata.com/download-free-sample/4572
The Centers for Disease Control and Prevention (CDC)
recommends vaccination for the following groups:
1. All children aged 12 to 23 months.
2. Children and adolescents aged 2 to 18
who haven't been vaccinated.
3. Individuals at risk due to their
occupation.
4. Those in close contact with
international adoptees.
5. HIV-positive individuals.
6. Patients with chronic liver disease.
Major Factors Driving Growth of the Global Hepatitis A
Vaccine Market:
1. High disease prevalence: Increasing
disease prevalence enhances health awareness, contributing positively to market
revenue growth.
2. Government efforts: Supportive
government vaccination initiatives, including free or reduced-cost vaccines,
are expected to boost demand for Hepatitis A vaccines. Governments also run
public awareness campaigns and immunization plans against Hepatitis A.
Factors Restraining Growth of the Global Hepatitis A Vaccine
Market:
1. High development costs: The
development of vaccines is a costly and rigorous process that involves
extensive research, experimentation, certification, government approvals, and
compliance with regulations.
2. Stringent regulations: Vaccine
production necessitates substantial research, ongoing development, and
adherence to government requirements and regulations, which can impede market
growth.
Opportunities for Players in the Global Hepatitis A Vaccine
Market:
1. Increased health awareness: A growing
focus on health and medical awareness creates business opportunities for both
established and new market players. Collaboration between governments and
private players in vaccination campaigns further supports market expansion.
Global Hepatitis A Vaccine Market Revenue by Product Type
Segment: The inactivated vaccine segment is expected to dominate revenue
generation during the forecast period. Inactivated vaccines are known for their
safety and effectiveness, with a single dose often being sufficient for stable
patients.
Global Hepatitis A Vaccine Market Led by Industry Type
Segment: Government institutions are anticipated to lead in revenue generation
over the forecast period, as public healthcare facilities play a critical role
in Hepatitis A diagnosis and vaccination. Government vaccination campaigns are
also expected to drive segment growth.
Asia Pacific Leads in Global Hepatitis A Vaccine Market
Revenue Share: Asia Pacific held the largest market share in 2020, driven by a
rising pediatric population and growing awareness of vaccination benefits.
Government-led vaccination initiatives in emerging economies like India and
China contribute to market growth in the region.
North America Leads in Revenue CAGR: North America is
expected to experience the highest revenue CAGR due to advancements in the
healthcare sector, increased prevalence of chronic diseases, higher healthcare
spending, and the presence of key market players.
Major Companies Profiled in the Report:
1. Kaketsuken
2. Merck & Company
3. Zhejiang Pukang Biotechnology Company
Ltd.
4. Sinovac Biotech Ltd.
5. Changchun Institute of Biological
Products Corporation Ltd.
6. IMBCA
7. Sanofi
8. GlaxoSmithKline
Strategies and Objectives of Major Companies: GlaxoSmithKline
plc is a pharmaceutical company specializing in pharmaceutical medications,
vaccines, and consumer healthcare products. The company's core segments are
Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team.
It produces a range of vaccines, including those for Hepatitis A and B,
diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid,
influenza, and bacterial meningitis.
HAVRIX, a Hepatitis A virus vaccine by GlaxoSmithKline, is
approved for individuals aged at least 12 months and is administered at least
two weeks before potential exposure to HAV.
What Our Report Provides and Why Our Offering Is Superior:
The report offers historical data and forecasts, providing insights into
revenue growth at global, regional, and country levels. It covers industry trends,
consumption patterns, and analysis for each region, major country, and segment
from 2018 to 2028. The report includes a detailed view of the global market,
competitive landscape, company financials, and impact analysis.
Detailed Segmentation in Our Report: The global Hepatitis A
vaccine market is segmented based on product type, industry type, channel type,
and region:
Product Type Outlook (Revenue, USD Billion; 2018-2028)
1. Inactivated vaccine
2. Live attenuated vaccine
Industry Type Outlook (Revenue, USD Billion; 2018-2028)
1. Government Institution
2. Private Sector
Channel Type Outlook (Revenue, USD Billion; 2018-2028)
1. Direct Sales
2. Distributor
Region Outlook (Revenue, USD Billion; 2018-2028)
1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa
Explore Trending Reports:
Autoimmune
Disease Diagnosis Market-https://www.globenewswire.com/news-release/2020/08/20/2081722/0/en/Autoimmune-Disease-Diagnosis-Market-To-Reach-USD-7-37-Billion-By-2027-Reports-and-Data.html
Protein
Expression Market-https://www.globenewswire.com/en/news-release/2021/04/19/2212656/0/en/Protein-Expression-Market-Size-to-Reach-USD-6-07-Billion-in-2028-CAGR-of-13-5-Reports-And-Data.html
Request a customization of the report:https://www.reportsanddata.com/request-customization-form/4572
Thank
you for reading our report. To know more about the customization or any query
about the report contents, please connect with us and our team will ensure the
report is tailored to meet your requirements.
About Reports and Data
Reports
and Data is a market research and consulting company that provides syndicated
research reports, customized research reports, and consulting services. Our
solutions purely focus on your purpose to locate, target, and analyse consumer
behaviour shifts across demographics, across industries, and help clients to
make smarter business decisions. We offer market intelligence studies ensuring
relevant and fact-based research across multiple industries, including
Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently
update our research offerings to ensure our clients are aware of the latest
trends existent in the market. Reports and Data has a strong base of
experienced analysts from varied areas of expertise. Our industry experience
and ability to develop a concrete solution to any research problems provides
our clients with the ability to secure an edge over their respective
competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press
Release: https://www.reportsanddata.com/press-release
The Wall